Skip to main content

Table 3 Characteristics of patients diagnosed with CD, Germany, 2000–2018

From: Describing nearly two decades of Chagas disease in Germany and the lessons learned: a retrospective study on screening, detection, diagnosis, and treatment of Trypanosoma cruzi infection from 2000 – 2018

Sexa Female
n = 52/81
(64.2%)
Male
n = 28/81
(34.6%)
All
n = 81
(100.0%)
Age in years at the time of testing
 Mean (SD) 43.3 years (SD = 3.8) 46.1 years (SD = 6.9) 44.0 years (SD = 3.4)
  ≤ 14 0 1 (3.6%) 1 (1.2%)
 15–49 35 (67.3%) 16 (57.1%) 51 (63.0%)
  ≥ 50 17 (32.7%) 11 (39.3%) 28 (34.6%)
 NA 0 0 1 (1.2%)
Nationality Available on n = 26/52 (50.0%) Available on n = 9/28 (32.1%) Available on n = 35/81 (43.2%)
 Bolivia 13 (50.0%) 7 (77.8%) 20 (57.1%)
 Germany 0 2 (22.2%) 2 (5.7%)
 Brazil 5 (19.2%) 0 5 (14.3%)
 Paraguay 2 (7.7%) 0 2 (5.7%)
 Argentina 3 (11.5%) 0 3 (8.6%)
 Peru 2 (7.7%) 0 2 (5.7%)
 South America 1 (3.8%) 0 1 (2.9%)
Reason for testing Available on n = 33/52 (63.5%) Available on n = 12/28 (42.9%) Available on n = 45/81 (55.6%)
 Known CD 17 (51.5%) 7 (58.3%) 24 (53.3%)
 Endemic national 7 (21.2%) 2 (16.7%) 9 (20.0%)
 Other 9 (27.3%) 3 (25.0%) 12 (26.7%)
Symptoms Available on n = 23/52 (44.2%) Available on n = 9/28 (32.1%) Available on n = 32/81 (39.5%)
 Fatigue 0 2 (22.2%) 2 (6.3%)
 Gastrointestinal 9 (39.1%) 2 (22.2%) 11 (34.4%)
 Cardiac 3 (13.0%) 0 3 (9.4%)
 Other 1 (4.3%) 2 (22.2%) 3 (9.4%)
 No symptoms 10 (43.5%) 3 (33.3%) 13 (40.6%)
Initial diagnosis of CD Available on n = 30/52 (57.7%) Available on n = 13/28 (46.4%) Available on n = 43/81 (53.1%)
 Yes 10 (33.3%) 5 (38.5%) 15 (34.9%)
 No 20 (66.7%) 8 (61.5%) 28 (65.1%)
Echocardiography Available on n = 18/52 (34.6%) Available on n = 5/28 (17.9%) Available on n = 23/81 (28.4%)
 Normal 16 (88.9%) 3 (60.0%) 19 (82.6%)
 Abnormal 0 1 (20.0%) 1 (4.3%)
 Not performed 2 (11.1%) 1 (20.0%) 3 (13.0%)
Electrocardiography Available on n = 18/52 (34.6%) Available on n = 9/28 (32.1%) Available on n = 27/81 (33.3%)
 Normal 16 (88.9%) 6 (66.7%) 22 (81.5%)
 Abnormal 2 (11.1%) 2 (22.2%) 4 (14.8%)
 Not performed 0 1 (11.1%) 1 (3.7%)
Etiologic treatment Available on n = 22/52
(42.3%)
Available on n = 7/28
(25.0%)
Available on n = 29/81
(35.8%)
 Benznidazole 8 (36.4%) 3 (42.9%) 11 (37.9%)
 Nifurtimox 2 (9.1%) 0 2 (6.9%)
 No treatment 12 (54.5%) 4 (57.1%) 16 (55.2%)
Treatment course Available on n = 8/10 (80.0%) Available on n = 1/3 treatments
(33.3%)
Available on n = 9/13 treatments (69.2%)
 Completed treatment 5 (62.5%) 0 5 (55.6%)
 Stopped treatment 3 (37.5%) 1 (100%) 4 (44.4%)
Side effects Available on n = 3/10 treatments
(30.0%)
Available on n = 1/3 treatments
(33.3%)
Available on n = 4/13 treatments
(30.8%)
 Yes 3 (100%) 1 (100%) 4 (100%)
 No 0 0 0
Reason for no treatment Available on n = 11/12 (91.7%) Available on n = 4/4
(100%)
Available on n = 15/16 (93.8%)
 Recommendations-based reason 5 (45.5%) 2 (50.0%) 7 (46.7%)
 Non-recommendations-based reason 6 (54.5%) 2 (50.0%) 8 (53.3%)
Follow-up Available on n = 13/52 (25.0%) Available on n = 4/28 (14.3%) Available on n = 17/81 (21.0%)
 >  12 months 7 (53.8%) 3 (75.0%) 10 (58.8%)
 ≤ 12 months 4 (30.8%) 1 (25.0%) 5 (29.4%)
 No follow-up 2 (15.4%) 0 2 (11.8%)
  1. ain one CD case none of the data was available; CD Chagas disease, NA Not available, SD Standard deviation